Mainz Biomed (MYNZ) Stock Price, News & Analysis

Company Overview

Mainz Biomed N.V. is a molecular genetics diagnostics company focused on improving the early detection of colorectal cancer. The company develops noninvasive diagnostic tests designed to identify disease-associated genetic markers from stool samples, with the goal of making screening more accessible and convenient.

Its principal product is ColoAlert, a home-based, laboratory-processed stool DNA test for colorectal cancer screening. The test analyzes molecular biomarkers associated with colorectal cancer and advanced adenomas, allowing individuals to collect samples at home and send them to a laboratory for analysis. ColoAlert has been available in Germany and other European markets under applicable regulatory requirements.

Mainz Biomed was founded in 2016 and is based in Mainz, Germany. The company has pursued regulatory authorization and commercial expansion in the United States, including clinical development of its ColoAlert technology through the eAArly DETECT study. Mainz Biomed’s broader strategy centers on developing molecular diagnostic products that support earlier cancer detection and complement existing screening methods.

Key Stats

• Today's Range: $1.30 to $1.36
• 50-Day Range: $1.06 to $1.60
• 52-Week Range: $0.55 to $4.43
• Volume: 242,520 shs
• Average Volume: 371,589 shs
• Market Capitalization: $11.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Mainz Biomed Stock Analysis - MarketRank™

Mainz Biomed scored higher than 6% of companies evaluated by MarketBeat, and ranked 636th out of 657 stocks in the industrials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Mainz Biomed has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Mainz Biomed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mainz Biomed are expected to grow in the coming year, from ($23.60) to ($9.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mainz Biomed is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mainz Biomed is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mainz Biomed has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MYNZ.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mainz Biomed does not currently pay a dividend.

Dividend Growth

Mainz Biomed does not have a long track record of dividend growth.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: N/A

News Sentiment

Mainz Biomed has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Industrials companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Mainz Biomed this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mainz Biomed insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.20% of the stock of Mainz Biomed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Mainz Biomed has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/15/2023
• Today: 9/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Industrials
• Industry: Aerospace & Defense
• Sub-Industry: Aerospace & Defense
• Current Symbol: NASDAQ:MYNZ
• CIK: 1874252
• Web: mainzbiomed.com
• Phone: 49-6131-554-2860
• Fax: N/A
• Employees: 30
• Year Founded: 2021

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.44
• Current Ratio: 0.52
• Quick Ratio: 0.43

Sales & Book Value

• Annual Sales: $659.94 thousand
• Price / Sales: 18.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.61 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 9,060,000
• Free Float: 7,411,000
• Market Cap: $11.96 million
• Optionable: Not Optionable
• Beta: 0.31